Navigation Links
TenX Biopharma Licenses Zanolimumab From Genmab
Date:2/4/2010

PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN).

Under the terms of the agreement, Genmab will receive an up-front license fee of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab.  TenX will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.  

"Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate," said Gardiner F.H. Smith, Chief Executive Officer of TenX Biopharma. "We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency."

Asher Nathan, Managing Partner of Zoticon Bioventures and the lead investor in TenX, said "TenX and zanolimumab represent the fourth late stage drug funding which we've led in the past two years.  I'm delighted that this important product will be available in the future, and look forward to the management team at TenX continuing to build value with novel cancer therapeutics."

"Genmab is pleased to find a partner who wishes to take zanolimumab forward in development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer.  "This is good news for patients who may one day benefit from treatment with zanolimumab."

About TenX

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.  For more information visit www.tenxbiopharma.com.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.  For more information visit www.genmab.com.

This press release contains forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. TenX does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Contact:  Gardiner F.H. Smith, Chief Executive Officer, TenX Biopharma

T: (304) 982-1240; E: gsmith@tenxbiopharma.com

SOURCE TenX Biopharma, Inc.

RELATED LINKS
http://www.tenxbiopharma.com

'/>"/>

SOURCE TenX Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017  ivWatch LLC, a medical device company focused ... therapy, is pleased to announce it was the Bronze ... Supplies and Equipment at the 2017 Medical Design Excellence ... industry. The award was presented by Medical Device and ... in New York during MD&M ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... ANGELES , June 8, 2017   Responding to ... drug oversight and the death of singer Chris Cornell ... on Human Rights International offers a free online ... better educate consumers and families about psychotropic drug risks. ... Ledger , who died from an accidental overdose, has called ...
Breaking Medicine Technology:
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... ... Men’s Health Month and the focus is on prostate cancer. Second only to ... the third most common cause of cancer related death today; lung cancer remains in the ... with prostate cancer during his lifetime. Those at highest risk are men who ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating ... outdoors. Home and business owners should be aware that the summer months provide more ... fact, mechanical locks and keys can be negatively affected from direct exposure to the ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
Breaking Medicine News(10 mins):